The purpose of this study is to test prevention strategies for pregnancy-related malaria.
Researchers will compare different malaria treatments and treatment schedules which include
chloroquine therapy (weekly doses versus being dosed twice during pregnancy for 3 days each
time) to the standard practice of preventive treatment intervals in pregnancy (with the drug
sulfadoxine-pyrimethamine given twice during pregnancy). Participants will include 900
pregnant women, who will be assigned to one of three treatment groups. Blood samples will be
collected at every visit before birth and any time the participant is ill to determine if
malaria is present. Pregnant women will be monitored during pregnancy and newborns will be
assessed at birth and followed until about 14 weeks. Participant involvement in the study is
expected to last about 12 months.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Chloroquine Chloroquine diphosphate Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine